

A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem

(host–microbial cross-talk/germ-free mice/*Bacteroides thetaiotaomicron*/transcriptional repressors/epithelial fucosylated glycan synthesis)

LORA V. HOOPER*, JIAN XU*, PER G. FALK*†, TORE MIDTVEDT‡, AND JEFFREY I. GORDON*§

*Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO 63110; and †Laboratory of Medical Microbial Ecology, Karolinska Institute, SE-17177 Stockholm, Sweden

Communicated by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, June 21, 1999 (received for review April 21, 1999)

ABSTRACT Little is known about how members of the indigenous microflora interact with their mammalian hosts to establish mutually beneficial relationships. We have used a gnotobiotic mouse model to show that *Bacteroides thetaiotaomicron*, a component of the intestinal microflora of mice and humans, uses a repressor, FucR, as a molecular sensor of L-fucose availability. FucR coordinates expression of an operon encoding enzymes in the L-fucose metabolic pathway with expression of another locus that regulates production of fucosylated glycans in intestinal enterocytes. Genetic and biochemical studies indicate that FucR does this by using fucose as an inducer at one locus and as a corepressor at the other locus. Coordinating this commensal's immediate nutritional requirements with production of a host-derived energy source is consistent with its need to enter and persist within a competitive ecosystem.

Humans must adapt to life in a microbial world. As adults, the number of microbes associated with our mucosal surfaces exceeds our total number of somatic and germ cells by more than an order of magnitude (1). The gastrointestinal tract is home to our most complex and populous society of microbes. The composition of the microflora varies along the length of the gut and during the life of the host. The microflora provides a functional barrier to colonization by pathogens (2, 3), plays an important role in normal nutrition and metabolism, and is thought to help shape development of the intestine's mucosal immune system (4). Despite its importance, almost nothing is known about the molecular mechanisms that allow components of the microflora to interact with their hosts so as to establish relationships that are advantageous to both. Understanding such relationships is important in considering the origins of opportunistic infections, various immunopathologic states, and the propagation of antibiotic-resistant organisms (2–8).

Assembly of the gut microflora commences at birth. When space and nutrients are not limiting, commensals with high division rates predominate. As the population increases and nutrients are depleted, niches become occupied with more specialized species (4). One conceptualization of how this process may be orchestrated is that the distribution of early-colonizing gut commensals is defined by a preformed nutrient foundation that has been laid down by the host. The ability of other commensals to enter occupied habitats would depend on their ability to utilize these nutrient substrates more efficiently and/or to engineer alterations in the nutrient reservoir to better suit their own metabolic capacities. In a mutualistic relationship, coordination of microbial nutrient utilization and host nutrient production should be achieved at a minimal energetic cost to microbe and host and not be deleterious to either.

To test this notion at a cellular and molecular level, we created a simplified model intestinal ecosystem by using germ-free mice that were colonized with a genetically manipulable species that normally resides in the distal intestine of mice and humans. We reported previously (9) that the microflora orchestrates a developmentally regulated program of fucosylated glycan production in the distal small intestinal (ileal) epithelium of mice belonging to the NMRI strain. Conventionally raised mice initiate production of Fuc α 1,2Gal-containing glycans in the principal epithelial lineage (enterocytes) during the weaning period. Expression of these glycans begins in enterocytes overlying scattered ileal villi and can be detected with the Fuc α 1,2Gal β -specific lectin, *Ulex europaeus* type I agglutinin (UEA-I). Induction commences on postnatal day 17 (P17) and generalizes by P25 to involve all enterocytes overlying all ileal villi. This induction represents a replacement of UEA-I-negative enterocytes with new UEA-I-positive enterocytes and is accompanied by transcriptional activation of a host α 1,2-fucosyltransferase gene. In the presence of a microflora, fucosylated glycoconjugate expression is sustained in rapidly renewing enterocytes throughout adulthood (9).

Germ-free mice are also able to initiate production of Fuc α 1,2Gal-glycans, beginning at the same time as conventionally raised mice. However, in the absence of a microflora, production ceases by the end of weaning (P28). Nonetheless, the capacity of ileal enterocytes to synthesize Fuc α 1,2Gal-glycans is maintained in adult germ-free animals because introduction of a conventional flora at any point after P28 reinitiates production (9).

Bacteroides thetaiotaomicron is an abundant member of the normal mouse and human distal small intestinal microflora (10, 11). It can scavenge a wide variety of host cell glycans *in vitro* and *in vivo* (12). Colonization of adult germ-free NMRI mice with *B. thetaiotaomicron* reproduces the cellular, spatial, and kinetic features of fucosylated glycan induction orchestrated by a complete microflora (9). Induction depends on the density of colonizing organisms and does not involve direct bacterial binding to the intestinal epithelium. Fu-4 is a *B. thetaiotaomicron* strain, generated by random transposon (Tn4351)-mediated mutagenesis, that is unable to grow in media containing L-fucose as the sole carbon source (12). The Fu-4 strain is also unable to signal host production of fucosylated glycans, even at high colonization densities (9). This report provides a molecular explanation for the connection between fucose utilization by *B. thetaiotaomicron* and

Abbreviations: Fuc, fucose; Gal, galactose; UEA-I, *Ulex europaeus* type I agglutinin; P, postnatal day; kb, kilobases; GUS, β -glucuronidase; cfu, colony-forming units.

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AF137263).

†Present address: Department of Gastrointestinal Pharmacology, AstraZeneca, S-431 83 Mölndal, Sweden.

§To whom reprint requests should be addressed at: Department of Molecular Biology and Pharmacology, Box 8103, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110. E-mail: jgordon@molecool.wustl.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at www.pnas.org.

its ability to instruct the host to produce hydrolyzable fucosylated glycans.

MATERIALS AND METHODS

Isolation of the *B. thetaiotaomicron* Fucose Utilization Gene Cluster. Tn4351 contains a unique *Hind*III site 3.5 kilobases (kb) from its 3' end, allowing the intact tetracycline-resistance gene (*tetX*) to be recovered within a single *Hind*III fragment that encompasses flanking chromosomal DNA (13). Southern blot analysis of Fu-4 DNA indicated that *tetX* was contained in a single 4.44-kb *Hind*III fragment. *Hind*III-digested Fu-4 DNA was size-fractionated, and the fragments were subcloned into pBluescript II KS (Stratagene). A plasmid (pBS-tetR), recovered from a tetracycline-resistant *Escherichia coli* transformant, contained a 4.44-kb insert that included 962 bp of genomic DNA flanking the 3' end of the transposon.

To isolate the corresponding locus from the isogenic wild-type *B. thetaiotaomicron* strain VPI-5482 (Anaerobe Laboratory, Virginia Polytechnic Institute and State University, Blacksburg, VA), 325 bp of the cloned genomic sequence (probe A) was amplified from pBS-tetR by using PCR (primers: 5'-GATATT-ATGTAACCAAGTCAGGT-3' and 5'-TCATCAAATCCTG-ACAGATAT-3'). The product hybridized to a 4-kb *Cla*I-*Sal*I fragment generated from VPI-5482 DNA. Therefore, *Cla*I-*Sal*I-digested genomic DNA was size-selected and subcloned into pBluescript II KS. Colony hybridization with probe A yielded pBS-bt1 with a 4-kb insert and pBS-bt4 with an overlapping 4.6-kb *Sca*I fragment containing the upstream portion of a fucose-utilization gene cluster. The downstream portion of the cluster was obtained by PCR amplification of a 402-bp fragment from the 3' end of the pBS-bt1 insert (primers: 5'-TCGACAGGACT-AATCCTGTTTC-3' and 5'-TCTGCTATCGGGATGCTCG-AAC-3'). This PCR product (probe B) was used to identify and subclone a 6.5-kb *Hind*III genomic fragment into pBluescript II KS (pBS-bt3).

Generation of Isogenic Mutant *B. thetaiotaomicron* Strains. The suicide vector pGERM was produced by A. Salyers (Univ. of Illinois, Champaign-Urbana) by first blunt-ending a *Nco*I-*Pst*I fragment carrying the erythromycin-resistance gene, *ermG* (14) and ligating it into the *Ssp*I site of pUC19 [pUC19(*ermG*)]. A *Hae*II fragment carrying *oriT*(RK2) (15) was then blunt-ended and ligated into the *Sap*I site of pUC19(*ermG*) to yield pGERM.

An internal fragment from each ORF of the *B. thetaiotaomicron* fucose-utilization gene cluster was amplified by PCR using primers containing *Eco*RI sites at their 5' ends and a single-bp mutation to produce an in-frame stop codon. The amplified fragments were cloned into the *Eco*RI site of pGERM. The resulting constructs were used to transform *E. coli* S17-1, which contains a chromosomal copy of the *Tra*⁺ plasmid RP4 (16). Transformants were used as donors in matings with *B. thetaiotaomicron* strain VPI-5482 (17). After plating on trypticase-yeast extract-glucose (TYG) agar containing erythromycin (10 µg/ml), transconjugants were assessed for their ability to grow on defined medium (18) containing 0.5% L-fucose or L-rhamnose as the sole carbon source. Genomic DNAs prepared from transconjugants were analyzed by Southern blotting for insertion of pGERM at the appropriate chromosomal locations.

Strains containing an *E. coli* β-glucuronidase (GUS) transcriptional reporter were constructed as follows. A 1.8-kb *Xba*I-*Hind*III fragment containing GUS was released by digestion from pGJL1 (kindly provided by A. Salyers). The fragment was then ligated to the *Xba*I-*Hind*III site of a suicide vector (pBT-1; ref. 19), yielding pBT1-GUS. The 422-bp sequence located directly upstream of the *fucR* start codon was inserted 5' to GUS, yielding pBT1-FuP/GUS. Transconjugations were performed as above, and transconjugants were selected on TYG agar containing 3 µg/ml tetracycline (and 10 µg/ml erythromycin for the *fucR*::pGERM recipient).

Enzymatic Assays. Wild-type and mutant *B. thetaiotaomicron* strains were grown to mid-logarithmic phase in defined medium containing 0.5% L-rhamnose with or without 0.5% L-fucose. Cells were disrupted by sonication. L-fucose isomerase activity was measured in cleared bacterial lysates by assaying the rate of formation of L-fucose with the cysteine-carbazole method (20). Permease activity was quantitated by monitoring the uptake of L-[6-³H]fucose by intact logarithmic-phase cells (12). α-L-Fucosidase activity in culture supernatants was assayed at pH 7 in 0.1 M sodium phosphate, by using 1 mM 4-methylumbelliferyl-α-L-fucopyranoside as the substrate (21).

ORFs from the *B. thetaiotaomicron* fucose-utilization operon were amplified by PCR, subcloned into pET3a (Stratagene), sequenced, and the plasmids were introduced into *E. coli* strain BL21 (DE3) (Stratagene). Isomerase, kinase, and aldolase activities were assayed in cleared lysates prepared from bacteria that had been grown to mid-logarithmic phase in defined medium (18) and treated with isopropyl-β-D-thiogalactoside (IPTG) for 3 h. L-Fucose kinase activity was determined from the rate of ADP formation in a coupled assay by using β-NADH, pyruvate kinase, and lactate dehydrogenase (22). L-Fucose-1-phosphate aldolase activity was assayed by measuring dihydroxyacetone phosphate formation in a coupled reaction with purified α-glycerophosphate dehydrogenase and β-NADH (23). All assays were done in the linear range of product formation.

Purification and Characterization of FucR. *E. coli* strain BL21(DE3) containing pET3a-*fucR* was grown to mid-logarithmic phase, and FucR production was induced with IPTG. The protein was then purified to apparent homogeneity by using a protocol described for *E. coli* TrcR (24). Antibodies to purified FucR were raised in rabbits by Cocalico Biologicals (Reamstown, PA).

Interactions between FucR and various monosaccharides were characterized by ligand-dependent quenching of the intrinsic fluorescence spectrum by using a PTI 01-610 fluorometer (Photon Technology International, Princeton). All assays were performed at 22°C in 2.5-ml reactions containing buffer A (100 mM KCl/10 mM MgCl₂/50 mM Tris-HCl, pH 7.5), 1.1 µM purified FucR, and varying amounts of saccharide. Samples were excited at 280 nm, and emission was monitored at 340 nm.

The state of FucR oligomerization was determined by dynamic light scattering (DynaPro-801, Protein Solutions, Charlottesville, VA) and by sedimentation equilibrium analysis (Beckman XL-A Optima analytical ultracentrifuge). Data obtained from the sedimentation studies ([FucR] = 10 µM) were analyzed by using the program SEDNTERP (25).

Interactions between FucR and its target DNA sequences were assessed initially by gel mobility-shift assays performed in 15-µl reactions containing buffer A, a ³²P-labeled restriction fragment or double stranded oligonucleotide, purified FucR (0.18–180 nM), a potential monosaccharide ligand (0.1–1000 µM), 0.3 mg/ml BSA, 0.13 mg/ml poly(dI,dC), and 10% glycerol. After incubation at 30°C for 1 h, the labeled species were separated by electrophoresis through 4% polyacrylamide gels. Subsequent DNase I footprint analyses were carried out according to ref. 26.

Colonization of Germ-Free NMRI Mice. Germ-free NMRI/KI mice (9) were housed in gnotobiotic isolators under a strict 12-h light cycle and fed an autoclaved chow diet (Lactamin, Vadstena, Sweden) *ad libitum*. Males (30–90 days old) were inoculated with wild-type or mutant *B. thetaiotaomicron* strains by spreading organisms from stationary-phase cultures on their fur. Animals were sacrificed 10 days later, and the number of colony-forming units (cfu) per ml of ileal contents was determined by serial dilution plating. All isogenic strains were tested in parallel with their wild-type parent (*n* = 4–5 animals per group per experiment; 2–3 experiments per mutant). Intestines from mice colonized with >10⁷ cfu/ml ileal contents at the time of sacrifice were scored for Fucα1,2Gal-glycans by staining whole-mount preparations with peroxidase-conjugated UEA-I (9).

RESULTS

Tn4351 Disrupts the L-Fucose Isomerase Gene (*fucI*), Which Is Part of a Fucose-Utilization Gene Cluster. We began our analysis of the connection between fucose utilization by *B. thetaiotaomicon* and its ability to instruct the host to produce hydrolyzable fucosylated glycans by determining that Tn4351 had been inserted 445 bp downstream of the start codon of an ORF. This ORF encodes a 591-aa protein having 63% identity with *E. coli* L-fucose isomerase (27). The genomic sequence adjacent to the site of transposon insertion was used subsequently to isolate, from the wild-type strain VPI-5482 (9), a gene cluster containing five closely spaced ORFs. Three of the ORFs have homology to *E. coli* (and other bacterial) genes that encode the key enzymes in fucose metabolism: L-fucose isomerase, L-fuculose kinase, and L-fuculose-1-phosphate aldolase (Fig. 1A). The identities of the *B. thetaiotaomicon* genes were confirmed by overexpressing their protein products in *E. coli*. The genes were named *fucI*, *fucA*, and *fucK* based on the nomenclature used in *E. coli* (27). A fourth ORF situated immediately upstream of *fucI* encodes a 331-aa protein whose N-terminal sequence is similar to the helix–turn–helix motif of members of the gluconate repressor (GntR) family of bacterial regulatory proteins (ref. 28; Fig. 1B). This gene was named *fucR*. *B. thetaiotaomicon* *FucR* is not homologous to *E. coli* *FucR*, the transcriptional activator of *E. coli*'s fucose-utilization pathway genes (29). A fifth ORF begins 418 bp downstream from the stop codon of *fucK* and specifies a protein with homology to *E. coli* L-fucose permease (*FucP*) (Fig. 1A).

Each of the five ORFs was disrupted by single-crossover homologous recombination of a suicide vector (pGERM) with strong transcription terminators. Integration of pGERM will have a polar effect on transcription of any downstream genes contained within an operon. Insertion of pGERM into *fucR*, *fucI*, *fucA*, *fucK*, or *fucP* abolished the ability of *B. thetaiotaomicon* to grow on defined medium containing L-fucose as the sole carbon source, but had no effect on the ability of the organism to grow on the related methyl pentose, L-rhamnose (data not shown).

FucR Functions as a Repressor of the *fucRIAK* Operon. To examine how expression of this gene cluster is regulated, a DNA fragment encompassing the 422 bp 5' to the *fucR* start codon was linked to *E. coli* GUS, and the construct was integrated, by single-crossover homologous recombination, just upstream of the gene cluster in isogenic wild-type and *fucR::pGERM* strains. Integration resulted in duplication of the 422-bp sequence (Fig. 2A) and did not affect growth of the strain with a wild-type background on medium containing fucose as the sole carbon source.




FIG. 1. *B. thetaiotaomicon* L-fucose-utilization gene cluster. (A) ORFs and the site of Tn4351 insertion. The bacterial L-fucose metabolic pathway is shown. The product of an ORF terminating 177 bp upstream of *fucR* shows homology to the 30S ribosomal protein S16 from several species. Another ORF beginning 187 bp downstream of *fucP* shares homology with several RNA polymerase σ factors. The GenBank accession number for this 10671-bp locus is AF137263. (B) Amino acid sequence of *FucR*. The underlined region encompasses a helix–turn–helix DNA binding region conserved in GntR family members.

RNase protection assays indicated that GUS mRNA levels were higher when wild-type cells were grown in the presence of L-fucose than when grown in its absence. In contrast, GUS transcription in cells lacking *FucR* was equivalent in the presence or absence of fucose (Fig. 2A). The constitutive pattern of GUS expression in the strain lacking *FucR* demonstrates that *FucR* is a repressor that regulates transcription from a fucose-inducible promoter located upstream of its own ORF.

Western blot analysis confirmed that *FucR* expression in wild-type *B. thetaiotaomicon* is induced by L-fucose (Fig. 2B). Enzymatic assays demonstrated that *FucI* is also inducible by fucose and that disruption of *fucI* by pGERM reduces isomerase activity to below the limits of detection. A similar reduction was observed in the Fu-4 strain (Fig. 2C). Disruption of *fucR* by pGERM abolishes expression of *FucR* and markedly reduces isomerase activity (Fig. 2B and C).

A genetic experiment established that *fucRIAK* forms an operon. The block in fucose utilization produced by disrupting *fucR* or *fucI* was not complemented by a shuttle vector containing a genomic fragment encompassing the fucose-responsive promoter plus *fucRI* but was overcome with a fragment encompassing the promoter plus *fucRIAK* (Fig. 2D).

Disruption of *fucP* results in a reduced rate of [3 H]L-fucose uptake relative to the wild-type strain (Fig. 2E). [3 H]L-fucose uptake in the *fucI::pGERM* strain is equivalent to that in the wild-type strain (Fig. 2E), indicating that *fucP* is regulated by a promoter that is distinct from *P_{RIAK}*.

Fucose Binds to *FucR* and Blocks Its Ability to Bind Target DNA Sequences. *FucR* was produced in *E. coli* and purified to apparent homogeneity. *FucR* binds to a DNA fragment encompassing the 283-bp sequence located upstream of the *fucR* initiator Met codon. Binding is inhibited by L-fucose in a dose-dependent fashion, but is not affected by L-fuculose, L-fuculose-1-phosphate, L-rhamnose, or D-glucose (Fig. 3A). DNA footprint analysis allowed us to identify the site of fucose-responsive *FucR* binding as 5'-TGCTGAGCTATGCTGTTGC-3'.

Fluorescence spectroscopy revealed that *FucR* binds L-fucose with a K_d of 10 μ M (Fig. 3B). Consistent with the results of the DNA gel-shift experiments, L-fuculose and L-fuculose-1-phosphate do not cause a significant change in the intrinsic fluorescence spectrum of *FucR*, even at 1 mM. Sedimentation equilibrium studies disclosed that the protein exists in solution as a dimer ($K_d = 0.6 \mu$ M) with or without bound L-fucose (data not shown).

We concluded that in *B. thetaiotaomicon*, L-fucose induces expression of the fucose pathway enzymes (and *FucR*) by binding to the *FucR* repressor and reducing its interaction with a fucose-inducible promoter (*P_{RIAK}*). Thus, expression of *FucR* is auto-regulated. The organization and regulation of the *B. thetaiotaomicon* fucose-utilization gene cluster differs markedly from that of *E. coli*, where two divergently transcribed operons are regulated by an activator (29) and where L-fucose-1-phosphate, rather than L-fucose, functions as the inducer (30).

FucR Regulates Another Genetic Locus Required for Microbial Signaling to the Host. To understand how regulation of *fucRIAK* is related to generation of a microbial signal that induces host fucosylated glycan synthesis, we compared glycan production in germ-free NMRI mice that had been colonized with the various isogenic strains ($n = 90$ animals). Mice were sacrificed 10 days after strain inoculation, and *Fuc* α 1,2Gal-glycan production in the intestinal epithelium was defined by staining with UEA-I. Previous experiments (9) had demonstrated that at least 10^7 cfu of the wild-type strain per ml of ileal contents was necessary to induce full expression of host *Fuc* α 1,2Gal-glycans. Therefore, we only scored mice that had achieved that colonization density.

As expected, no UEA-I staining was seen in the small intestines of germ-free controls ($n = 5$; Fig. 4A). Six of seven mice with $>10^7$ cfu of wild-type *B. thetaiotaomicon* per ml of ileal contents exhibited uniform UEA-I staining of their ileal villus enterocytes. There was also uniform staining in four of seven mice colonized




FIG. 2. FucR functions as a repressor of the *fucRIAK* operon. (A) Transcription reporter assay. Strains BT7 (wild-type background) and BT11(*fucR*::pGERM background) contain an integrated chromosomal copy of GUS fused to 422 bp of sequence that is normally located directly upstream of the *fucR* start codon. Note that integration produces a duplication of the 422-bp element, with one copy linked to GUS and the other copy remaining at its endogenous location. GUS




FIG. 3. L-Fucose binds to FucR and causes it to dissociate from the fucose pathway promoter. (A) Gel mobility-shift assay. A ³²P-labeled DNA fragment, corresponding to the 283 bp of sequence 5' to the initiator Met codon of *fucR*, was incubated with 30 ng of purified FucR and 1 mM of L-fucose, L-fucose, L-fucose-1-phosphate, D-glucose, or L-rhamnose. (B) Determination of L-fucose binding affinity by ligand-dependent quenching of FucR's intrinsic fluorescence spectrum (see Materials and Methods).

with *fucA*::pGERM and in five of five mice harboring *fucK*::pGERM. In contrast, all mice containing Fu-4 (*n* = 4) or *fucI*::pGERM (*n* = 7) had no, or rare, UEA-I-positive villi (Fig. 4A). Retention of gene disruptions in bacteria recovered from ileal contents was confirmed by plating on defined medium containing fucose as the sole carbon source and by Southern blot analysis of chromosomal DNA.

These results indicated that L-fucose isomerase plays a key role in determining whether this organism is able to signal its host to synthesize fucosylated glycans. The product of the isomerase, L-fucose, could play a role in signal generation either by (i) interacting directly with the intestinal epithelium, (ii) becoming a

mRNA was detected by RNase protection, and signals were compared with those obtained by using a probe to 30S ribosomal protein S16 (*rp16*) mRNA. The results are representative of three independent experiments. (B) FucR expression. Strains were grown to mid-logarithmic phase on defined medium, with or without L-fucose. Soluble cellular proteins (10 μg per lane) were separated by SDS/PAGE. Western blots were prepared and probed with a rabbit antiserum generated against purified FucR. (C) Assays of cellular L-fucose isomerase activity from mid-logarithmic phase cultures of isogenic strains. (D) Evidence that *fucA* and *fucK* are expressed cotranscriptionally with *fucRI*. The shuttle vector pLYL01 containing *fucRIAK* rescues the ability of the *fucI*::pGERM strain to grow on defined medium containing L-fucose, whereas *fucRI* does not. (E) L-Fucose permease activity in cells recovered from mid-logarithmic phase cultures of wild-type and mutant strains.




FIG. 4. Regulation of Fuc α 1,2Gal-containing glycan production in the ileum of germ-free NMRI mice. (A) Representative whole-mount preparations of ileum obtained 10 days after inoculation of the indicated strain and stained with peroxidase-conjugated UEA-I (brown). Villi appear as finger-like projections. (B). Model for the coordinate regulation of bacterial fucose metabolism with host fucosylated glycan production. L-fucose acts through FucR both as the inducer of transcription of *fucRIAK* and as a corepressor of transcription at *csp*, which is directly or indirectly responsible for production of a bacterial signal that results in increased production of host fucosylated glycoconjugates.

substrate for another bacterial metabolic pathway that converts it to a signaling molecule, or (iii) acting as the inducer of a pathway involved in signal production through interactions with a transcriptional regulator encoded by another locus. To determine whether any of these possibilities applies, we tested the ability of the *fucR*::pGERM strain to signal up-regulation of Fuc α 1,2Gal-glycans. As noted above, pGERM disruption of *fucR* eliminates production of FucR, FucI, FucA, and FucK, but not FucP. Remarkably, seven of seven germ-free mice colonized by *fucR*::pGERM at $>10^7$ cfu/ml showed uniform UEA-I staining of the ileal epithelium (Fig. 4A). This observation establishes that L-fucose is not directly involved in bacterial signal production and eliminates *i-iii*. It also indicates that FucR mediates repression of at least one other genetic locus, in addition to *fucRIAK*, that either regulates or is directly involved in production of the signal that leads to synthesis of Fuc α 1,2Gal-glycans. We designated this second FucR-responsive locus *control of signal production (csp)* and postulated that when FucR is absent, repression at *csp* is relieved and signaling to the epithelium ensues.

Genetic Evidence That L-Fucose Functions as a Corepressor with FucR at *csp*. Fig. 4B presents a model consistent with the experimental results. A key feature of the model is that L-fucose functions as an inducer of the *fucRIAK* operon by reducing FucR binding to P_{RIAK} and as a corepressor at *csp* by enhancing FucR binding to P_{csp} . An autoregulatory bacterial repressor that functions to suppress metabolism of its inducer at one locus and uses this inducer as a corepressor at another locus would be novel. This regulatory strategy would result in maintenance of intracellular *B. thetaiotaomicron* fucose concentrations at a particular "set point", determined in large part by the affinity of FucR for fucose (10

μ M) and by the affinity of the fucose-bound form of FucR for the *csp* promoter. If intracellular fucose levels rise above this set point, the proportion of FucR in the fucose-bound form increases, resulting in decreased binding of the repressor to P_{RIAK} and an increased rate of fucose degradation. The other consequence is increased binding of FucR at the *csp* promoter (i.e., there is no need to signal the host for more fucose). Conversely, if fucose levels fall below the setpoint, the proportion of unbound FucR will increase, resulting in increased binding to the fucose pathway promoter (reflecting a decreased need to metabolize fucose) and decreased binding at the *csp* promoter (a "request" to the host for more fucose). Because transcription of *fucP* is independent of *fucRIAK* transcription, disruption of *fucI* has no effect on the rate of L-fucose uptake (see Fig. 2E). According to the model, disruption of *fucI* results in a strain in which imported L-fucose cannot be metabolized, accumulates within the cell, and is available to interact with FucR to repress *csp*. The presence of the isomerase in strains that lack *fucA* and/or *fucK* would still allow conversion of L-fucose to L-fuculose, thereby preventing L-fucose from accumulating and decreasing repression of *csp* by FucR.

Because our model predicts that low intracellular fucose levels will stimulate signal production, we used the *fucP*::pGERM strain to examine the effects of reducing fucose import on signaling. Three of four mice colonized with $>10^7$ cfu/ml of *fucP*::pGERM exhibited Fuc α 1,2Gal-glycan production throughout their distal small intestine (Fig. 4A), supporting the model. A further prediction from the model is that abolishing fucose uptake in the *fucI*::pGERM strain will convert it from a non-signaling to a signaling strain. This prediction was confirmed when four of four mice colonized with $>10^7$ cfu/ml of a *fucP*::pBT-1 *fucI*::pGERM double mutant were found to have uniform UEA-1 staining of their ileal epithelium (Fig. 4A).

Evidence that L-Fucose Is an Important Carbon Source for *B. thetaiotaomicron* in the Distal Small Intestine Under Competitive, Nutrient-Limiting Conditions. A final *in vivo* experiment indicated that the ability to utilize fucose confers a competitive advantage under nutrient-limiting conditions. Germ-free mice ($n = 10$; two independent experiments) were inoculated with *fucI*::pGERM. This strain was selected because it lacks all three fucose-metabolizing enzymes. Ten days later, the animals were subjected to a 24-h fast to simulate a competitive ecosystem in which dietary carbohydrates are scarce. Control mice, colonized with the same strain, were given free access to chow during this 24-h period. Insertion of pGERM (containing an erythromycin-resistance gene) by single crossover into *fucI* not only results in loss of FucI, FucK, and FucA, but causes partial duplication of the targeted locus. *In vitro* cultivation of *fucI*::pGERM cells for 40 generations in the absence of antibiotic disclosed a constant frequency of spontaneous vector removal (10^{-7}) that did not confer a simple growth advantage. *In vivo*, we found that there was a statistically significant ($P < 0.05$) 3-fold increase in the number of fucose-utilizing/erythromycin-sensitive organisms after food deprivation. Southern blotting confirmed that the capacity to utilize fucose and erythromycin sensitivity were linked to loss of pGERM. These observations support the notion that fucose utilization is advantageous to this organism when it is subjected to nutrient deprivation in the gut. However, we cannot formally exclude the less likely possibility that fasting, *per se*, somehow leads to an enhanced frequency of reversion of a pGERM insertion.

Fucose is almost always a terminal, α -linked sugar in mammalian glycoconjugates. Therefore, a secreted bacterial α -fucosidase should be sufficient to obtain monosaccharidic fucose for import and metabolic processing (31, 32). Additional exo- or endoglycosidases are not needed, thereby minimizing the investment required for the microbe to obtain fucose as an energy source. Consistent with this notion, we found that wild-type, *fucR*::pGERM, and *fucI*::pGERM strains all secrete α -fucosidase

activity when grown in defined medium, in either the presence or absence of fucose (data not shown).

DISCUSSION

By colonizing germ-free mice with *B. thetaiotaomicon*, we have been able to generate a simplified model ecosystem that allows molecular definition of the interactions between a resident bacterial species and the intestinal epithelium. In this partnership, the host appears to be an active participant in providing for the nutritional needs of at least one of its resident commensals. In addition, the bacterium is able to actively determine the degree to which its nutritional needs are met. A key feature of the signal-transduction pathway is that L-fucose acts through FucR both as an inducer of *fucRLAK*, and as a corepressor of another locus, *control of signal production*.

It is reasonable that *B. thetaiotaomicon* would turn to epithelial fucosylated glycans as a source of energy in the highly competitive intestinal ecosystem. Strict anaerobes, including *Bacteroides* species, typically colonize the mammalian intestine during weaning (1). The intestinal ecosystem is densely populated at this point with the preweaning microflora, likely limiting the availability of simple sugars needed for continued growth of the bacterial population. The ability to instruct the host to present a source of utilizable carbohydrate should confer a competitive advantage under these conditions. Fucose is a logical choice. It is a normal and abundant component of many host intestinal cell-surface glycoconjugates (31, 32). Moreover, many of the core oligosaccharide structures to which fucose is commonly linked are constitutively synthesized, so presentation of fucose may only require induction of one or more host fucosyltransferases.

Our findings are compatible with the notion that the intestine provides a nutrient foundation that helps program assembly and preservation of a microbial society during the weaning transition. At early stages of colonization, the *B. thetaiotaomicon* population density is presumably inadequate to generate sufficient amounts of a concentration-dependent microbial signal to increase the availability of hydrolyzable fucose in its habitat. However, the presence of a preformed pool of Fuc α 1,2Gal-containing glycans in scattered ileal villi may provide sufficient hydrolyzable fucose to promote initiation and early progression of *B. thetaiotaomicon* colonization. Once a critical density of organisms is attained, the population can signal sustained production of an adequate supply of host-derived fucose. Signaling to the host only when fucose availability declines below a certain set point ensures that *B. thetaiotaomicon* will avoid expending valuable energy on signal production when fucose is abundant. By tightly coordinating presentation of host-derived fucose with the rate of fucose utilization, an overabundance of hydrolyzable epithelial fucose is also avoided. This may minimize the risk of encroachment by pathogens that use fucosylated glycans as receptors for their adhesins (33, 34).

We do not know whether the relationship between *B. thetaiotaomicon* and its host is symbiotic (both partners benefit) or commensal (neither is harmed). The host may benefit in several ways from filling its intestinal habitat with *B. thetaiotaomicon* at the weaning transition. During this time of great compositional flux in the microflora, *B. thetaiotaomicon* could help direct assembly of a stabilized microflora that provides colonization resistance. Additional benefits may include provision of critical metabolic activities and shaping of the underlying mucosal immune system. The paradigm illustrated by this host-microbial relationship may apply to other nutrient sources, other components of our microflora, and other mucosal surfaces.

We are indebted to Abigail Salyers and Nadja Shoemaker (University of Illinois, Champaign-Urbana) for their gifts of pLYL01, pGERM, pBT1, and strain Fu-4, plus their many helpful suggestions throughout the

course of our studies. A.-K. Persson assisted with colonization of germ-free mice. Chi-Huey Wong (Scripps Institute) generously supplied L-fucose and L-fucose-1-phosphate. This work was supported by grants from the National Institutes of Health (DK30292, DK37960). L.V.H. was supported by postdoctoral fellowships from the Lucille P. Markey Foundation and the National Institutes of Health (DK07120).

1. Savage, D. C. (1977) *Annu. Rev. Microbiol.* **31**, 107–133.
2. Van der Waaij, D. (1989) *Annu. Rev. Microbiol.* **43**, 69–87.
3. Araneo, B. A., Cebra, J. J., Beuth, J., Fuller, R., Heidt, P. J., Midvedt, T., Nord, C. E., Nieuwenhuis, P., Manson, W. L., Pulverer, G., *et al.* (1996) *Zentralbl. Bakteriologie* **283**, 431–465.
4. Falk, P. G., Hooper, L. V., Midvedt, T. & Gordon, J. I. (1998) *Microbiol. Mol. Biol. Rev.* **62**, 1157–1170.
5. Kühn, R., Löhler, J., Rennick, D., Rajewski, K. & Müller, W. (1993) *Cell* **75**, 263–274.
6. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C. & Horak, I. (1993) *Cell* **75**, 253–261.
7. Taugou, J. D., Richardson, J. A., Croft, J. T., Simmons, W. A., Zhou, M., Fernandez-Sueiro, J. L., Balish, E. & Hammer, R. E. (1994) *J. Exp. Med.* **180**, 2359–2364.
8. Hunter, A. E., Haynes, A. P. & Russell, N. H. (1995) *J. Antimicrob. Chemother.* **36**, Suppl. B, 119–133.
9. Bry, L., Falk, P. G., Midvedt, T. & Gordon, J. I. (1996) *Science* **273**, 1380–1383.
10. Moore, W. E. C. & Holdeman, L. V. (1974) *Appl. Microbiol.* **27**, 961–979.
11. Ushijima, T., Takahashi, M., Tatewaki, K. & Ozaki Y. (1983) *Microbiol. Immunol.* **27**, 985–993.
12. Salyers, A. A. & Pajean, M. (1989) *Appl. Environ. Microbiol.* **55**, 2572–2578.
13. Cheng, Q., Hwa, V. & Salyers, A. A. (1992) *J. Bacteriol.* **174**, 7185–7193.
14. Cooper, A. J., Shoemaker, N. B. & Salyers, A. A. (1996) *Antimicrob. Agents Chemother.* **40**, 506–508.
15. Guiney, D. G. & Jakobson, E. (1983) *Proc. Natl. Acad. Sci. USA* **80**, 3595–3598.
16. Simon, R., Priefer, U. & Puhler, A. (1983) *Bio/Technology* **1**, 784–791.
17. Shoemaker, N. B., Getty, C., Gardner, J. F. & Salyers, A. A. (1986) *J. Bacteriol.* **166**, 929–936.
18. McCarthy, R. E. & Salyers, A. A. (1986) *Appl. Environ. Microbiol.* **52**, 9–16.
19. Tancula, E., Feldhaus, M. J., Bedzyk, L. A. & Salyers, A. A. (1992) *J. Bacteriol.* **174**, 5609–5616.
20. Dische, Z. & Borenfreund, E. (1951) *J. Biol. Chem.* **192**, 583–587.
21. Aviles, M., Abascal, I., Martinez-Menarguez, J. A., Castells, M. T., Skalan, S. R., Ballesta, J. & Alhadeff, J. A. (1996) *Biochem. J.* **318**, 821–831.
22. Anderson, R. L. & Wood, W. A. (1962) *J. Biol. Chem.* **237**, 1029–1033.
23. Ghalambor, M. A. & Heath, E. C. (1962) *J. Biol. Chem.* **237**, 2427–2433.
24. Horlacher, R. & Boos, W. (1997) *J. Biol. Chem.* **272**, 13026–13032.
25. Herr, A. B. & Waksman, G. (1999) *Methods Mol. Med.*, in press.
26. Brenowitz M., Senear D. F., Shea M. A. & Ackers G. K. (1986) *Methods Enzymol.* **130**, 132–181.
27. Lu, Z. & Lin, E. C. C. (1989) *Nucleic Acids Res.* **17**, 4883–4884.
28. Haydon, D. J. & Guest, J. R. (1991) *FEMS Microbiol. Lett.* **63**, 291–295.
29. Chen, Y.-M., Zhu, Y. & Lin, E. C. C. (1987) *Mol. Gen. Genet.* **210**, 331–337.
30. Bartkus, J. M. & Mortlock, R. P. (1986) *J. Bacteriol.* **165**, 710–714.
31. Björk, S., Breimer, M. E., Hansson, G. C., Karlsson, K.-A. & Leffler, H. (1987) *J. Biol. Chem.* **262**, 6758–6765.
32. Finne, J., Breimer, M. E., Hansson, G. C., Karlsson, K.-A., Leffler, H., Vliegthart, J. F. & van Halbeek, H. (1989) *J. Biol. Chem.* **264**, 5720–5735.
33. Benitez, J. A., Spelbrink, R. G., Silva, A., Phillips, T. E., Stanley, C. M., Boesman-Finkelstein, M. & Finkelstein, R. A. (1997) *Infect. Immun.* **65**, 3474–3477.
34. Brassart, D., Woltz, A., Golliard, M. & Nesser, J. R. (1991) *Infect. Immun.* **59**, 1605–1613.